Streamlining Humana Xarelto Prior Authorization Workflows

Understanding Xarelto Coverage by Humana

Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) commonly prescribed for indications such as atrial fibrillation and venous thromboembolism (VTE) treatment and prevention. As a high-cost medication, Xarelto typically requires prior authorization from Humana to ensure medical necessity and adherence to formulary guidelines. While specific formulary tiers and quantity limits can vary, many DOACs, including rivaroxaban, may be subject to step therapy requirements under Humana's plans, particularly within their extensive Medicare Advantage portfolio.

Humana Prior Authorization Submission Channels for Xarelto

Humana leverages multiple channels for prior authorization submissions, depending on the benefit and service type. For Xarelto, which is typically covered under the pharmacy benefit, primary submission pathways include electronic prior authorization (ePA) and direct PBM interaction. Medical-benefit services, if applicable, route through different channels.

Key Submission Pathways for Humana PA

• **Pharmacy Benefit (Part D & Commercial):** Submissions route through Humana's pharmacy benefit operation. Prescriber-initiated ePA workflows are supported via CoverMyMeds and Surescripts ePA platforms.
• **Specialty Pharmacy:** For certain complex or high-cost medications, CenterWell Specialty Pharmacy handles specialty injectables and complex medications on the pharmacy benefit.
• **Medical Benefit (if applicable):** While Xarelto is primarily a pharmacy benefit drug, any associated medical services requiring PA would route through Humana's medical PA channel, often via Availity Essentials for commercial and Medicare Advantage lines, or through X12 278 transactions via clearinghouses.
• **Inpatient/Concurrent Review:** For patients admitted to an inpatient setting, concurrent review intake follows documented pathways on the Humana provider site, with distinct notification timeframes.

Accessing Humana's Utilization Management Policies for Rivaroxaban

Humana publishes medical policy and coverage determination documents on its provider site, which should be referenced by specific policy or coverage-determination number and effective date. For Medicare Advantage plans, coverage policies must align with CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). Humana's medical policies often disclose whether criteria are Humana-developed, MCG-based, or NCCN-compendium-based, providing transparency into the decision-making framework for drugs like Xarelto.

Turnaround Times and CMS-0057-F Impact on Humana PA

Humana publishes precertification turnaround commitments on its provider site. For its significant Medicare Advantage enrollment, CMS-mandated timeframes apply: historically 14 calendar days for standard pre-service decisions and 72 hours for expedited. CMS-0057-F, which applies broadly to Humana's Medicare Advantage PA operations as an impacted payer, will further tighten these to 7 calendar days for standard PA and 72 hours for expedited decisions, with phased compliance through 2027. This regulatory shift underscores the need for robust electronic prior authorization capabilities.

Common Denial Reasons and Appeal Pathways for Xarelto with Humana

Denials for Xarelto prior authorizations from Humana are typically returned via X12 277/835 transactions or portal status updates. Common reasons include insufficient documentation of medical necessity, failure to meet NCD/LCD criteria for MA lines, or non-compliance with step therapy requirements. For Medicare Advantage lines, the appeal pathway follows the CMS-mandated 5-level structure (reconsideration through judicial review), while commercial appeals follow distinct pathways. Peer-to-peer reviews and expedited appeals are generally available across lines of business.